Acadia Pharmaceuticals Inc’s Sentiment
“Big money sentiment for Acadia Pharmaceuticals Inc (NASDAQ:ACAD) in 2018 Q2 increased to 1.22, according to SEC.gov filings. So its up 0.33, from 2018Q1’s 0.89. 90 institutional investors increased and opened new equity positions, while 74 sold and decreased positions in Acadia Pharmaceuticals Inc so the sentiment has increased. Funds own 114.30 million shares, down from 119.37 million shares in 2018Q1. Funds holding Acadia Pharmaceuticals Inc in top 10 increased from 1 to 2 for an increase of 1. 31 Investors Sold All; 43 Reduced Holdings; 55 increased stakes while 35 institutional investors bought stakes.
Most Acadia Pharmaceuticals Inc Investors
As of 2018 Q2 Great Point Partners Llc has 4.23% invested in Acadia Pharmaceuticals Inc. Acadia Pharmaceuticals Inc’s shareholder Baker Bros. Advisors Lp owns 27.23 million shares as of 2018 Q2. Furthermore, Ghost Tree Capital Llc reported 535,000 shares in Acadia Pharmaceuticals Inc equivalent to 2.4% of its long stock exposure. First Washington Corp revealed 264,760 shares position in Acadia Pharmaceuticals Inc. The Georgia-based fund Emory University looks positive on Acadia Pharmaceuticals Inc, owning 144,125 shares.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.The firm is worth $2.36 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of ParkinsonÂ’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of AlzheimerÂ’s disease psychosis.Currently it has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.
ACAD is hitting $18.86 during the last trading session, after decreased 2.03%.Currently ACADIA Pharmaceuticals Inc. is downtrending after 62.95% change in last November 10, 2017. ACAD has also 2.17 million shares volume. ACAD underperformed the S&P 500 by 78.57%.
Bogle L P De accumulated 270,715 shs. 498,339 are owned by Jpmorgan Chase Co. Cim Invest Mangement stated it has 0.08% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). New York-based Morgan Stanley has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). First Washington Corporation owns 264,760 shs for 2% of their capital. Products Prns Limited Liability Company owns 681,500 shs for 0.4% of their capital. Price T Rowe Assoc Incorporated Md stated it has 0% of its capital in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Wells Fargo And Mn stated it has 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Tower Research Cap Lc (Trc) invested in 0% or 13 shs. 91,230 were accumulated by Art Advsrs Limited Liability Company. Public Employees Retirement Association Of Colorado holds 0% or 18,333 shs. Ser Automobile Association has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Blackrock Inc reported 9.74M shs stake. 148,748 are held by Amer Century Incorporated. San Francisco Sentry Inv Gru (Ca) owns 0.01% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 2,325 shs.
ACADIA Pharmaceuticals Inc. had 0 insider sales and 1 buying transaction since September 20, 2018. This’s net activity of $22.65 million.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage
A total of 5 analysts rate ACADIA Pharmaceuticals (NASDAQ:ACAD) as follows: 4 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 80% are bullish. (NASDAQ:ACAD) has 8 ratings reports on 10 Nov 2018 according to StockzIntelligence. On Monday, August 6 the company was downgraded by PiperJaffray. In Tuesday, October 16 report Cantor Fitzgerald maintained it with “Overweight” rating and $27 target. On Thursday, August 9 JMP Securities maintained the shares of ACAD in report with “Market Outperform” rating. In Thursday, November 1 report Cantor Fitzgerald maintained it with “Overweight” rating and $30 target. On Wednesday, October 10 the firm has “Buy” rating by Bank of America given. On Friday, September 21 PiperJaffray upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to “Overweight” rating.
More recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were announced by Seekingalpha.com, Seekingalpha.com and Seekingalpha.com. The first one has “ACADIA Pharma up 11% premarket on positive mid-stage pimavanserin data in MDD” as a title and was announced on October 31, 2018. The next is “Acadia Pharma finance chief bids adieu” on October 29, 2018. And last was announced on November 08, 2018, called “ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q3 2018 Results – Earnings Call Transcript”.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.